321 search results for “cancer drug resistance” in the Staff website
-
Mario van der Stelt
Science
m.van.der.stelt@chem.leidenuniv.nl | +31 71 527 4768
-
Roxanne Kieltyka
Science
r.e.kieltyka@chem.leidenuniv.nl | +31 71 527 4441
-
Gerard van Westen
Science
gerard@lacdr.leidenuniv.nl | +31 71 527 3511
-
Madeline Kavanagh
Science
m.e.kavanagh@lic.leidenuniv.nl | +31 71 527 3527
-
Eline Dekeyster
Faculteit der Sociale Wetenschappen
e.a.g.dekeyster@fsw.leidenuniv.nl | +31 71 527 2727
-
Review paper on the potential impact drug-metabolizing enzymes on brain exposure
PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.
-
Universiteit Leiden Announce Collaboration to Develop Advanced Polyaminoacid Drug Delivery Systems
Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…
-
Dutch Cancer Society allocates funds to a mathematician: for treating Ewing sarcoma with the help of an app
If doctors could better estimate a patient's chances of survival, this would help in choosing a specific treatment. It would be particularly beneficial for the rare and malignant Ewing sarcoma, which mainly affects children and adolescents. Mathematics professor Marta Fiocco has been awarded a substantial…
-
Arteriosclerosis and drug discovery: two young researchers win Krijn Rietveld Award for innovative research
One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.
-
Medical Delta AI for Computational Life Sciences
The fact that scientists are increasingly better able to access molecular cell and tissue data also brings with it a new challenge: how can scientists find the information they need for research among the vast amount of data available?
-
Lioe-Fee de Geus-Oei
Faculteit Geneeskunde
l.f.de_geus-oei@lumc.nl | +31 71 526 9111
-
Improving nature’s antibiotic
'What nature made isn’t necessarily an optimized medicine to use in the human body,’ says Professor of Biological Chemistry Nathaniel Martin. That’s why a group of Leiden researchers is making a chemistry-based improved version of the frequently used antibiotic vancomycin. They received an NWO NACTAR…
-
Remarkable PhD research: diagnosing sepsis in premature babies
How can we diagnose the life-threatening condition sepsis in premature babies as quickly and accurately as possible? That is what PhD student Manchu Thangavelu from the Leiden Academic Centre for Drug Research (LACDR) wants to figure out.
-
Skin researcher calls for multidisciplinary collaboration: ‘I want to pool expertise’
In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…
-
Coen van Hasselt
Science
coen.vanhasselt@lacdr.leidenuniv.nl | +31 71 527 3266
-
Anthe Janssen
Science
a.p.a.janssen@lic.leidenuniv.nl | +31 71 527 4362
-
Joost Batenburg
Science
k.j.batenburg@liacs.leidenuniv.nl | +31 71 527 6985
-
Seeking new concepts to treat diseases
Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’
-
Neske Baerwaldt
Faculteit Rechtsgeleerdheid
n.baerwaldt@law.leidenuniv.nl | +31 71 527 2727
-
innovative phage-antibiotic combination treatments to combat antimicrobial resistance
Phage therapy is a novel yet unmatured therapeutic approach in the face of the crisis of antimicrobial resistance (AMR). Dr. Tingjie Guo received a grant from the Elise Mathilde Fund and the LUF to develop innovative phage-antibiotic combination treatment strategy for combating AMR.
-
Nature Communications paper on therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression
Cancer immunotherapy represents a significant breakthrough in cancer treatment. However, tumors have numerous mechanisms by which they evade destruction by the immune system. It is therefore necessary to decipher and reverse these mechanisms in order to improve immunotherapies.
-
for effective application of a new revolutionary cholesterol lowering drug resides in a 30 year old Leiden Patent
‘’ And then the world changed forever ,welcome to the future’’. These are the words that Kausik Ray (President of the European Atherosclerosis Society) spoke when the worldwide first dose of inclisiran, a novel SiRNA based cholesterol lowering agent, was administered at the Cardiology lipid clinic at…
-
Antibiotics of the future: looking for a new way to kill bacteria
Current antibiotics only address very few target proteins in bacteria to kill them. Researchers know that there are more possible target proteins to tackle the bacteria. The question is: which ones. Thanks to the NWO Vidi Grant, Assistant Professor Molecular Physiology Stephan Hacker and his team can…
-
Sebastian Pomplun
Science
s.j.pomplun@lacdr.leidenuniv.nl | +31 71 527 4651
-
Improving Nature’s Antibiotics to Overcome Resistant Bacteria
Lecture, NGL-lezing
-
Babak Rezaeedaryakenari
Faculteit der Sociale Wetenschappen
s.rezaeedaryakenari@fsw.leidenuniv.nl | +31 70 800 3687
-
Elizabeth (Liesbeth) de Lange
Science
ecmdelange@lacdr.leidenuniv.nl | +31 71 527 6330
-
The molecular secrets of medicinal cannabis
Chronic pain, nausea or vomiting due to chemotherapy. If you suffer from such ailments, medicinal cannabis can be a godsend. Though a downside is that it can make patients high. Therefore, Leiden researchers from the Oncode Institute are investigating alternatives that do not make you high. In Nature…
-
Nicolas Rodriguez Idarraga
Faculty of Humanities
n.rodriguez.idarraga@hum.leidenuniv.nl | +31 71 527 2727
-
Bas ter Braak
Science
s.j.ter.braak@lacdr.leidenuniv.nl | +31 71 527 2727
-
Marije Niemeijer
Science
m.c.niemeijer@lacdr.leidenuniv.nl | +31 71 527 6105
-
Marcel Schaaf
Science
m.j.m.schaaf@biology.leidenuniv.nl | +31 71 527 4975
-
Thomas Hankemeier
Science
hankemeier@lacdr.leidenuniv.nl | +31 71 527 4226
-
Leiden researchers join forces against tuberculosis
About one and a half million people worldwide die each year from tuberculosis. For thirty years, therapy with antibiotics has been the same, while it takes far too long and can lead to resistant pathogens. Leiden researchers from four institutes are now joining forces to develop more effective and efficient…
-
ERC-grant for Sebastian Pomplun to cure disease by controlling gene expression with synthetic transcription factors
Sebastian Pomplun receives an ERC starting grant of 1.85 million Euros in five years. He wants to develop synthetic transcription factors that can enter cells and activate or deactivate specific genes. For example to disrupt cancer-related processes or to trigger the production of an important missing…
-
Steffen Brünle
Science
s.bruenle@lic.leidenuniv.nl | +31 71 527 4544
-
Review on “Anticancer opportunities at every stage of chemokine function” is featured on the cover of TIPS
Last November, Dr. Natalia Ortiz, Martijn Bemelmans (MSc), and Prof. Laura Heitman published a review in Trends in Pharmacological Sciences (TIPS) on targeting the chemokine system in cancer (https://doi.org/10.1016/j.tips.2021.08.001). The review was written in collaboration with Prof. Tracy Handel…
-
Regulation of signal transduction pathways by hypoxia in breast cancer subtypes
PhD defence
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
PhD defence
-
Strategic advice
Communication
-
Code of Conduct on Integrity
Anyone who comes into contact with Leiden University should be able to trust that we will act with integrity. The Code of Conduct on Integrity describes how we can work together to ensure that this is the case, whether in relation to research, interactions with students, purchasing or the use of University…
-
Fighting gliobastoma brain tumours with two grants
Few researchers see potential in research on glioblastoma, an incurable brain tumour. Alexander Kros brought together colleagues who are up to the challenge. European research funder ERC recently made 10.6 million euros available, a year earlier NWO provided 3 million euros. ‘In six years, we certainly…
-
Erik Danen new Dean of the Graduate School of Science
The Graduate School of Science starts 2024 with a new Dean. The Faculty Council appointed Erik Danen for the coming four years. He succeeds Eric Eliel, who has held the position since May 2020.
-
BRCA1-associated breast cancer: finding new weapons for an old villain
PhD defence
-
Disrupting the transcriptional machinery to combat triple-negative breast cancer
PhD defence
-
Cancer-induced somatic mutations in G protein-coupled receptors
PhD defence
-
Tom van der Wel
Science
t.van.der.wel@lic.leidenuniv.nl | +31 71 527 3527
-
Serkan Aslan
Science
s.aslan@lacdr.leidenuniv.nl | +31 71 527 5919
-
Madouc Bergers made her own enzyme inhibitors for her bachelor’s thesis
For her bachelor’s thesis, Molecular Science and Technology student Madouc Bergers synthesized her own molecule that can inhibit the breakdown of sugars. Although most students do not even manage to make one building block, Madouc made three. Partly because of this, she has been nominated for the Science…
-
Life after the Grand Jamboree: Wrapping-up iGEM
‘A challenging rollercoaster, but also a very bonding and insightful experience,’ that’s how the team of iGEM Leiden 2022 wraps up their participation in the iGEM contest. The contest for synthetic biology climaxed during the Grand Jamboree in Paris. The team ended up in the top 10 of over 360 teams…